KR890011840A - 1,4-이치환 -피페리디닐 화합물 - Google Patents

1,4-이치환 -피페리디닐 화합물 Download PDF

Info

Publication number
KR890011840A
KR890011840A KR1019890000597A KR890000597A KR890011840A KR 890011840 A KR890011840 A KR 890011840A KR 1019890000597 A KR1019890000597 A KR 1019890000597A KR 890000597 A KR890000597 A KR 890000597A KR 890011840 A KR890011840 A KR 890011840A
Authority
KR
South Korea
Prior art keywords
compound
group
fluorophenyl
halogen
lower alkyl
Prior art date
Application number
KR1019890000597A
Other languages
English (en)
Other versions
KR0131377B1 (ko
Inventor
에이.카 알버트
피.밀러 프랜시
알.니두작 세데우스
엠.소렌센 스테펜
Original Assignee
게리 디.스트리트
메렐 다우 파마슈티칼스 인크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 게리 디.스트리트, 메렐 다우 파마슈티칼스 인크 filed Critical 게리 디.스트리트
Publication of KR890011840A publication Critical patent/KR890011840A/ko
Application granted granted Critical
Publication of KR0131377B1 publication Critical patent/KR0131377B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

내용 없음

Description

1,4-이치환-피페리디닐 화합물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (23)

  1. 하기 구조식 Ⅰ 및 구조식 Ⅱ로 표시되는 화합물.
    (a) 상기 구조식 Ⅰ에서, R 및 R′는 각각 독립적으로 저급 알킬, 저급 알콕시, 수소 및 할로겐으로 되는 군중에서 선택되며; (b) 상기 구조식 Ⅱ에서, X는 카르보닐기 또는 히드록시 메틸렌기를 나타내고, A′는 할로겐, 저급 알킬 및 저급 알콕시로 되는 군 중에서 선택되는 적어도 하나의 치환체이고, A는 할로겐, 수소, 저급 알킬 및 저급 알콕시기로 되는 군 중에서 선택되나, 단 이때 X가 카르보닐기인 경우이고, A가 저급 알킬 또는 저급 알콕시기일 때에는, A′는 할로겐이 아니다.
  2. 제1항에 있어서, 상기 화합물이 α-(4-플루오로페닐)-4-[(4-플루오로페닐)히드록시메틸]-1-피페리딘에탄올인 화합물.
  3. 제1항에 있어서, 상기 화합물이 4-(히드록시페닐메틸)-α-페닐-1-피페리딘에탄올인 화합물.
  4. 제1항에 있어서, 상기 화합물이 α-(4-플루오로페닐)-4-(히드록시메틸)-1-피페리딘에탄올인 화합물.
  5. 제1항에 있어서, 상기 화합물이 (3,4-디메톡시페닐)[1-[2-(4-플루오로페닐) -2-히드록시에틸]-4-피페리디닐]메탄온인 화합물.
  6. 하기 구조식 Ⅵ의 4-치환 피페리딘을 구조식 Ⅶ의 펜아실 할라이드와 반응시키는 것으로 되는 하기 구조식 Ⅱ로 표시되는 화합물의 제조방법.
    상기 구조식에서, X는 카르보닐기 또는 히드록시메틸렌기를 나타내고, A'는 할로겐, 저급 알킬 및 저급 알콕시기로 되는 군 중에서 선택되는 적어도 하나의 치환체이고, A는 할로겐, 수소, 저급 알킬 및 저급 알콕시기로 되는 군 중에서 선택되나, 단 이때 X가 카르보닐기인 경우이고, A가 저급 알킬 또는 저급 알콕시기일 때에는, A'는 할로겐이 아니며, Y는 할로겐 원자이다.
  7. 하기 구조식 Ⅷ의 화합물을 환원하는 것으로 되는 하기 구조식 Ⅰ로 표시되는 화합물의 제조방법.
    상기 구조식에서, R 및 R'는 각각 독립적으로 저급 알킬, 저급 알콕시, 수소 및 할로겐으로 되는 군 중에서 선택된다.
  8. 통증의 경감을 요하는 환자에게 하기 구조식 Ⅴ의 화합물을 투여하여 통증을 경감시키는 방법.
    상기 구조식에서, Y는 히드록시메틸렌기 또는 카르보닐기를 나타내고, Z는 히드록시메틸렌기 또는 카르보닐기를 나타내고, D 및 D′는 각각 독립적으로 저급 알킬, 저급 알콕시, 할로겐 및 수소로 되는 군 중에서 선택되나, 단 다음과 같은 조건이 적용되는데, 즉 (ⅰ) Y와 Z가 모두 카르보닐기를 나타내고, D′가 할로겐인 경우에, D는 저급 알킬 또는 저급 알콕시기일 수 없으며, (ⅱ) Y가 카르보닐기를 나타내고, Z가 히드록시메틸렌기를 나타내는 경우에는, D와 D′가 모두 동시에 할로겐이 될 수 없다.
  9. 제8항에 있어서, 상기 화합물이 α-(4-플루오로페닐)-4-[(4-플루오로페닐)히드록시메틸]-1-피페리딘에탄올인 방법.
  10. 제8항에 있어서, 상기 화합물이 4-(히드록시페닐메틸)-α-페닐-1-피페리딘에탄올인 방법.
  11. 제8항에 있어서, 상기 화합물이 α-(4-플루오로페닐)-4-(히드록시페닐메틸)-1-피페리딘에탄올인 방법.
  12. 제8항에 있어서, 상기 화합물이 (3,4-디메톡시페닐)[1-[2-(4-플루오로페닐) -2-히드록시에틸]-4-피페리디닐]메탄온인 방법.
  13. 제8항에 있어서, 상기 화합물이 2-(4-벤조일-1-피페리디닐)-1-페닐-에탄온인 방법.
  14. 제8항에 있어서, 상기 화합물이 2-[4-(4-풀루오로벤조일)-1-피페리디닐]-1-(4-플루오로페닐)-에탄온인 방법.
  15. 제8항에 있어서, 상기 화합물이 1-(4-플루오로페닐)-2-[4-(4-플루오로페닐)히드록시메틸]-1-피페리디닐]-에탄온인 방법.
  16. 근육 강직을 나타내는 환자에게 하기 구조식 Ⅴ의 화합물을 투여하여 근육 강직을 경감시키는 방법.
    상기 구조식에서, Y는 히드록시메틸렌기 또는 카르보닐기를 나타내고, Z는 히드록시메틸렌기 또는 카르보닐기를 나타내고, D 및 D′는 각각 독립적으로 저급 알킬, 저급 알콕시, 할로겐 및 수소로 되는 군 중에서 선택되나, 단 다음과 같은 단서 조건이 적용되는데, 즉 (ⅰ) Y와 Z가 모두 카르보닐기를 나타내고, D′가 할로겐인 경우에, D는 저급 알킬 또는 저급 알콕시기일 수 없으며, (ⅱ) Y가 카르보닐기를 나타내고, Z가 히드록시메틸렌기를 나타내는 경우에는, D와 D′가 모두 동시에 할로겐이 될 수 없다.
  17. 제16항에 있어서, 상기 화합물이 α-(4-플루오로페닐)-4-[(4-플루오로페닐)히드록시메틸]-1-피페리딘에탄올인 방법.
  18. 제16항에 있어서, 상기 화합물이 4-(히드록시페닐메틸)-α-페닐-1-피페리딘에탄올인 방법.
  19. 제16항에 있어서, 상기 화합물이 α-(4-플루오로페닐)-4-(히드록시메틸)-1-피페리딘에탄올인 방법.
  20. 제16항에 있어서, 상기 화합물이 (3,4-디메톡시페닐)[1-[2-(4-플루오로페닐) -2-히드록시에틸]-4-피페리디닐]메탄온인 방법.
  21. 제16항에 있어서, 상기 화합물이 2-(4-벤조일-1-피페리디닐)-1-페닐-에탄온인 방법.
  22. 제16항에 있어서, 상기 화합물이 2-[4-(4-풀루오로벤조일)-1-피페리디닐]-1-(4-플루오로페닐)-에탄온인 방법.
  23. 제16항에 있어서, 상기 화합물이 1-(4-플루오로페닐)-2-[4-(4-플루오로페닐)히드록시메틸]-1-피페리디닐]-에탄온인 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890000597A 1988-01-21 1989-01-20 1, 4-이치환-피페리디닐 화합물 KR0131377B1 (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US14664788A 1988-01-21 1988-01-21
US143.647 1988-01-21
US146,647 1988-01-21
US07/279,900 US5064838A (en) 1988-01-21 1988-12-07 1,4-disubstituted-piperidinyl compounds as pain relievers
US279.900 1988-12-07
US297900 1988-12-07

Publications (2)

Publication Number Publication Date
KR890011840A true KR890011840A (ko) 1989-08-22
KR0131377B1 KR0131377B1 (ko) 1998-04-17

Family

ID=48782796

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890000597A KR0131377B1 (ko) 1988-01-21 1989-01-20 1, 4-이치환-피페리디닐 화합물

Country Status (18)

Country Link
US (1) US5064838A (ko)
EP (1) EP0325268B1 (ko)
JP (1) JP2967990B2 (ko)
KR (1) KR0131377B1 (ko)
CN (1) CN1035823A (ko)
AR (2) AR247385A1 (ko)
AT (1) ATE90077T1 (ko)
AU (1) AU615713B2 (ko)
CA (1) CA1330087C (ko)
DE (1) DE68906801T2 (ko)
DK (1) DK26389A (ko)
ES (1) ES2058346T3 (ko)
FI (1) FI90534C (ko)
HU (2) HU202494B (ko)
NO (1) NO174505B (ko)
NZ (1) NZ227643A (ko)
PH (1) PH27115A (ko)
PT (1) PT89497B (ko)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR910006138B1 (ko) * 1986-09-30 1991-08-16 에자이 가부시끼가이샤 환상아민 유도체
NZ236501A (en) * 1989-12-21 1992-12-23 Merrell Dow Pharma Piperidine derivatives and antithrombotic compositions
US5292752A (en) * 1989-12-21 1994-03-08 Merrell Dow Pharmaceuticals Inc. Antithrombotic compounds
JP2869512B2 (ja) * 1990-06-01 1999-03-10 メレルダウファーマスーティカルズ インコーポレイテッド （＋）―α―（２，３―ジメトキシフェニル）―１―［２―（４―フルオロフェニル）エチル］―４―ピペリジンメタノール
ES2096651T3 (es) * 1990-06-07 1997-03-16 Merrell Pharma Inc Derivados de 1-piperidinil alcanoilarilsulfonamida.
FR2672286B1 (fr) * 1991-01-31 1994-11-18 Synthelabo Derives de 1-(4-chlorophenyl)-2-[4-(phenylmethyl)piperidin-1-yl]ethanol, leur preparation et leur application en therapeutique.
WO1992020661A1 (en) * 1991-05-22 1992-11-26 Merck & Co., Inc. N, n-diacylpiperazines
FR2678269B1 (fr) * 1991-06-27 1995-01-13 Synthelabo Derives de 1-(4-chlorophenyl)-2-[4-(2-phenylethyl)piperidin-1-yl]ethanol, leur application et leur preparation en therapeutique.
US6048859A (en) 1992-06-29 2000-04-11 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
US5719147A (en) * 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
US5637699A (en) * 1992-06-29 1997-06-10 Merck & Co., Inc. Process for preparing morpholine tachykinin receptor antagonists
US5387595A (en) * 1992-08-26 1995-02-07 Merck & Co., Inc. Alicyclic compounds as tachykinin receptor antagonists
FR2696741B1 (fr) * 1992-10-12 1994-11-25 Synthelabo Dérivés de 1-(4-chlorophényl)-2-[4-[(4-fluorophényl)méthyl]piperidin-1-yl] éthanol, leur préparation et leur application en thérapeutique.
US5344830A (en) * 1992-12-10 1994-09-06 Merck & Co., Inc. N,N-diacylpiperazine tachykinin antagonists
US5348955A (en) * 1993-06-22 1994-09-20 Merck & Co., Inc. N,N-diacylpiperazines
US5610165A (en) * 1994-02-17 1997-03-11 Merck & Co., Inc. N-acylpiperidine tachykinin antagonists
IL112778A0 (en) * 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
EP0796619A1 (en) 1996-03-21 1997-09-24 Merrell Pharmaceuticals Inc. Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol in treating depressive disorders and bipolar disorders
US6028083A (en) * 1997-07-25 2000-02-22 Hoechst Marion Roussel, Inc. Esters of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol
DE69830045T2 (de) 1997-10-31 2006-01-12 Daiichi Suntory Pharma Co., Ltd. Arylpiperidinopropanol und Arylpiperazinopropanol Derivate und dieselbe ent- haltende Pharmazeutika
US6713627B2 (en) * 1998-03-13 2004-03-30 Aventis Pharmaceuticals Inc. Processes for the preparation of (R)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
US20050261341A1 (en) * 1998-03-13 2005-11-24 Aventis Pharmaceuticals Inc. Novel processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
US6277864B1 (en) 1998-08-28 2001-08-21 Aventis Pharmaceuticals Inc. Use of R- +)-α-(2,3-dimethoxyphenyl-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol for the treatment of sleep disorders
US6939879B2 (en) * 1998-08-28 2005-09-06 Aventis Pharmaceuticals Inc. Use of R (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of substance induced insomnia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3576810A (en) * 1968-06-20 1971-04-27 Robins Co Inc A H 1-substituted-3-(-4)-aroylpiperidines
GB1402889A (en) * 1973-02-03 1975-08-13 Ciba Geigy Ag Piperidine derivatives
FR2581993B1 (fr) * 1985-05-14 1988-03-18 Synthelabo Derives de (benzoyl-4 piperidino)-2 phenyl-1 alcanols, leur preparation et leur application en therapeutique
KR910006138B1 (ko) * 1986-09-30 1991-08-16 에자이 가부시끼가이샤 환상아민 유도체

Also Published As

Publication number Publication date
NZ227643A (en) 1991-01-29
HUT53871A (en) 1990-12-28
NO890269D0 (no) 1989-01-20
HU205073B (en) 1992-03-30
HU900238D0 (en) 1990-03-28
HU202494B (en) 1991-03-28
DE68906801T2 (de) 1993-09-23
EP0325268B1 (en) 1993-06-02
US5064838A (en) 1991-11-12
PT89497B (pt) 1994-03-31
JP2967990B2 (ja) 1999-10-25
DK26389D0 (da) 1989-01-20
FI890245A (fi) 1989-07-22
JPH01224360A (ja) 1989-09-07
DE68906801D1 (de) 1993-07-08
PH27115A (en) 1993-03-16
NO890269L (no) 1989-07-24
AU615713B2 (en) 1991-10-10
PT89497A (pt) 1989-10-04
FI890245A0 (fi) 1989-01-17
AU2868789A (en) 1989-07-27
ES2058346T3 (es) 1994-11-01
KR0131377B1 (ko) 1998-04-17
DK26389A (da) 1989-07-22
CA1330087C (en) 1994-06-07
HUT52050A (en) 1990-06-28
FI90534B (fi) 1993-11-15
ATE90077T1 (de) 1993-06-15
AR247385A1 (es) 1994-12-29
NO174505C (ko) 1994-05-18
NO174505B (no) 1994-02-07
EP0325268A1 (en) 1989-07-26
CN1035823A (zh) 1989-09-27
FI90534C (fi) 1994-02-25
AR244666A1 (es) 1993-11-30

Similar Documents

Publication Publication Date Title
KR890011840A (ko) 1,4-이치환 -피페리디닐 화합물
KR900006328A (ko) 2-아제티디논 유도체
KR890000465A (ko) 환상 아민 화합물
KR870007888A (ko) 피페리딘 유도체 및 그를 함유하는 제약 조성물
KR910009705A (ko) 수용성이 개선된 이미다조[4,5-b] 퀴놀리닐 옥시알칸산 아미드
KR950008510A (ko) 피페리딘 및 피페라진
DE69001006T2 (de) Verwendung von substituierten imidazolen zur herstellung eines analgetikums.
KR920701153A (ko) 옥시인돌 유도체
KR890005069A (ko) 치환된 1-[아르알킬- 피페라지노알킬]사이클로알칸올
YU2290A (en) Process for piperidine obtaining
ATE208392T1 (de) 1-(1,2-disubstituierte piperidinyl)-4- (kondensierte imidazole)-piperidin derivate
KR950701525A (ko) 간 손상 환자의 항히스타민제로서의 테르페나딘 유도체의 용도(Use of Terfenadine Derivatives as Antihistaminics in a Hepatically Impaired Patient)
KR890014114A (ko) 신경이완제 투여와 연관된 추체외로(extrapyramidal) 부작용의 치료방법
KR890008095A (ko) 1,4-이치환 피페리디닐 화합물
KR890009398A (ko) 불안증 치료방법
KR950016729A (ko) 유방 질환의 억제 방법
RU2319696C2 (ru) Цис-2, 4, 5-триарил-имидазолины
IE38907L (en) Tetrahydropyridine and piperidine derivatives.
DE05815687T1 (de) Verfahren zur herstellung von citalopram und enantiomeren
ATE79612T1 (de) Verfahren zur herstellung von alpha-(alkylphenyl)-4-(hydroxydiphenylmethyl)-1 piperidinbutanol.
KR900701774A (ko) 살진균성 벤조디옥산 아민 유도체
KR880002839A (ko) 신규한 α-치환된 케토니트론 유도체
KR840001161A (ko) 2-시클릭아미노-2-(1,2-벤지속사졸-3-일)아세트산 에스테르 유도체들의 제조방법과 조성물
KR880005130A (ko) 히스타민 h₁길항제
KR890009877A (ko) 1-아실-2-피라졸린유도체의 제조방법

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20021118

Year of fee payment: 6

LAPS Lapse due to unpaid annual fee